EXJADE® (Deferasirox) | Charting Treatment Success With The EXJADE Serum Ferritin Tracker

MENUEfficacy - IntroductionEfficacy - Chelation at Essential SitesEfficacy - Dose-Dependent ChelationEfficacy - Long-Term EfficacyEfficacy - 24-Hour Activity Efficacy - Clinical Trial SummariesSafety - Long-Term Safety ProfileSafety - Side Effect ManagementSafety - Monitoring GuidelinesSafety - Important Safety InformationDosing - Dosing GuidelinesDosing - Dose CalculatorDosing - Serum Ferritin TrackerPatient Types - IntroductionPatient Types - beta-ThalassemiaPatient Types - Myelodysplastic SyndromesPatient Types - Sickle Cell DiseasePatient Types - Other AnemiasPatient Types - IPSS CalculatorCompliance Support - IntroductionCompliance Support - Side Effect ManagementCompliance Support - Educational ToolsExjade Resources - Summary of Resources and ToolsExjade Resources - Related LinksExjade Resources - Mechanism of ActionAbout Iron Toxicity - Iron ToxicityAbout Iron Toxicity - Morbidity and MortalityAbout Iron Toxicity - Screening and MonitoringAbout Iron Toxicity - Managing Iron ToxicityExjade FAQsAbout Novartis OncologyContact UsSite MapTerms of UsePrivacy PolicyCountry Sites - CanadaCountry Sites - GermanyCountry Sites - JapanCountry Sites - NetherlandsCountry Sites - SwitzerlandCountry Sites - United StatesSwiss PIEU SmPCNovartis OncologyPubmedAre You An Exjade Prescriber Seeking Tips For Treatment Success?Are You Considering Exjade And Seeking Compelling Data?Are You A Researcher Seeking Exjade Information Resources?Swiss PIEU SmPCExjade Important Safety Information EXJADE is indicated for the treatment of chronic iron overload due to blood transfusions (transfusional hemosiderosis) in adult and pediatric patients (aged 2 years and over). Please click here for Swiss Prescribing Information. Please click here for EU SmPC. Please click here for Exjade Important Safety Information.References: 1. Cappellini MD, Cohen A, Piga A, et al. A phase 3 study of deferasirox (ICL670), a once-daily oral iron chelator, in patients with beta-thalassemia. Blood. 2006;107(9):3455-3462. 2. Eleftheriou P, Tanner M, Pennel D, Porter JB. Response of myocardial T2* to oral deferasirox monotherapy for 1 year in 29 patients with transfusion-dependent anaemias; a subgroup analysis [11th Congress of the European Hematology Association abstract 0999]. Haematologica. 2006;91(s1):366. 3. Wood J, Thompson AA, Paley C, et al. Exjade® reduces cardiac iron burden in chronically transfused beta-thalassemia patients: an MRI T2* study [American Society of Hematology 49th Annual Meeting abstract 2781]. Blood. 2007;110(11):817a. 4. EXJADE Swiss prescribing information. Berne, Switzerland: Novartis Pharma Schweiz Inc; 2008. Disclaimer: This is an international website for EXJADE, and is intended for healthcare professionals outside the U.S. If you are a U.S. resident, please click on the U.S. residents link at the top of this page. The information on this site is not country-specific, and may contain information that is outside the approved indications in the country in which you are located.© 2008 Novartis AG. Use of this website is subject to our Terms of Use. TOOLS TO HELP PATIENTS STAY MOTIVATED – AND ON THEIR EXJADE® THERAPYCharting treatment success with the EXJADE Serum Ferritin Tracker
Patients taking chronic therapy for an asymptomatic condition like iron toxicity do not feel the beneficial effects of their therapy, so they may need to see results in order to stay motivated to comply with treatment. Serum ferritin tests, which should be administered monthly, can show both you and your patients how well they are responding to EXJADE and whether a dose adjustment is needed.1
With the EXJADE Serum Ferritin Tracker , you can chart your patients’ progress on EXJADE and share the results with them at each visit. Seeing their iron levels go down over time can give your patients the reassurance they need that their therapy is working and the motivation to stay on it for the long term.
Patient education materials to help patients feel informed and empowered
EXJADE offers patient education materials so that once your patients leave your office with their EXJADE prescriptions, they will have easy access to the information and answers they need about their condition and their treatment. These materials include: Reference: 1.